Targeted Therapies for Solid Tumors

Tailoring Treatments for Individual Patients
In the race to find new oncology treatments, solid tumor clinical trials are continuing to pave the way in the discovery and approval of effective new anti-cancer therapies, including immunotherapies and other forms of innovative targeted approaches.

These new treatment paradigms require a deep therapeutic understanding and a high level of experience in the different therapeutic targets. Against evolving treatment landscapes and a backdrop of regulatory change, patient recruitment and retention require a specialist approach: one where the ability to connect with patients through investigative sites ranks as highly as medical and operational expertise.

As the Contract Research Organization (CRO) that investigators consistently choose to work with*, Syneos Health® will match your commitment to making a success of your trials.

* Voted CenterWatch “Top CRO to Work With” among top 10 global CROs in 2013, 2015 and 2017. Only CRO to be ranked in the top three CROs to work with, in every survey conducted, since survey began in 2007. The Society for Clinical Research Sites (SCRS) Eagle Award Winner in the CRO Category in 2017 and 2018. Source: CenterWatch Global Investigative Site Survey.

**93%**

Helped develop or commercialize **93% of Novel New Oncology Drugs** approved by the FDA and **88%** of products granted marketing authorization by the EMA in a recent five-year period

**Close ties to hundreds** of patient advocacy organizations, investigator cooperative groups and KOLs

**30 successful NDAs/sNDAs** across multiple tumor types

Provided clinical and commercial services for **6 of 7 Checkpoint Inhibitors** currently on the market
Understanding the Challenges of Personalized Medicine: Delivering Solid Tumor Clinical Trials

Highly effective, personalized, novel therapies based on tumor targets are now being developed and used. Studies are now designed to include multiple drugs and tailored treatments against heterogeneous malignancies that were previously considered to be one disease.

Immuno-oncology, targeted therapies and niche patient populations all require focus — and so should your study team. Our project teams concentrate exclusively on solid tumors. Our total solid tumor experience in the last five years spans 351 studies across more than 11,000 sites worldwide involving over 53,500 patients in a variety of solid tumor subtypes.

Our clinical professionals are currently supporting new approaches on personalized medicine in solid tumors, working with cutting-edge therapies, including combination immunotherapies, and complex study designs across all phases.

Mechanisms of Action (MoA) Tailored for Each Patient

Investigating new approaches on personalized medicine, from Early Phase to Phase IV. Innovation in monitoring of Oncology and Hematology toxicities: New and of special interest (TEAEs and AESIs)

In the last five years alone our targeted therapies experience in solid tumors includes 299 studies on 92 different biologic targets.

Syneos Health’s experience of the rapid advancements in solid tumor drug development and the understanding of how these will shape your study design and execution will provide your studies with the greatest chance of success. You will have access to expertise via our integrated Cross-Functional Consortia in a number of key strategic areas, including cell and gene therapies, rare diseases and pediatric oncology. Additionally, through our global regulatory consulting group, we can provide support and discussions with the main regulatory agencies regarding accelerated drug development pathways to help you with your clinical development planning.
Effective Trial Delivery

Identifying the right sites in the right place at the right time to recruit the right patients requires therapeutically aligned expertise and is never a matter of chance. We have introduced the use of big data sources as a tool to complement current approaches to site identification, as well as to gain greater access to protocol-eligible, de-identified patient population information. The objective is to utilize data and technology to enable Syneos Health to match the right patients to the right protocols and right investigators through the Syneos Health network of investigational oncology sites providing global coverage in all world regions.

Syneos Health Active Oncology Sites

![Syneos Health Active Oncology Sites](image)

Number of Sites Recruiting to Oncology Studies

<table>
<thead>
<tr>
<th>REGION</th>
<th># SITES</th>
</tr>
</thead>
<tbody>
<tr>
<td>NA</td>
<td>4,822</td>
</tr>
<tr>
<td>WEUR</td>
<td>4,086</td>
</tr>
<tr>
<td>APAC</td>
<td>2,443</td>
</tr>
<tr>
<td>CEE</td>
<td>1,198</td>
</tr>
<tr>
<td>LATAM</td>
<td>536</td>
</tr>
<tr>
<td>MENA</td>
<td>382</td>
</tr>
</tbody>
</table>

Data from: Aug. 9, 2019

Contact us:
+1 919 876 9300
syneoshealth.com

About Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Learn more about how we are shortening the distance from lab to life® at syneoshealth.com.

© 2019 Syneos Health®. All rights reserved.